Proteins and Peptide Drugs: Different Routes of Administration for Their Delivery
Abstract
Proteins and peptides have the wide range of therapeutic agents emerged within and the administration is through needle and syringe i.e., parenteral delivery is the choice of route of administration, but it has drawn some drawback related to patient incompliance such as causing pain during administration, sterility and cost of the product though the bioavailability is 100%. The route of administration plays an important role as it have an impact on the therapeutic outcome of the drug, with the advancement in the branch of pharmaceutical biotechnology. Based on the biophysical and biochemical properties a delivery system was designed for protein and peptide based therapeutic and clinical application have come into existence through non-invasive delivery and in addition, this dosage form can be significantly self-administered by patients, manufacturing cost would be less compared to the injections. The main aim is to focus in this review article is the recent advances in the delivery of therapeutic proteins and peptides via different non-invasive routes and the barriers affecting the drug transportation, approaches, advantages, challenges.
Keywords: Non-invasive drug delivery, therapeutic proteins and peptides, non-invasive routes.
Downloads
Download data is not yet available.
References
1. SP Chaudhari, MP Ratnaparkhi, Peptides and proteins in pharmaceuticals, International Journal of Current Pharmaceutical Research, 2011, 3(2), 1-9.
2. PK Sharma, Sumedha Bansal, Arunabha Banik, Noninvasive Routes of Proteins and Peptides Drug Delivery, Indian Journal of Pharmaceutical Sciences, 2011, 73(4), 367-75.
3. A.A. Kaspar, J.M. Reichert, Future directions for peptide therapeutics development, Drug Discovery Today, 2013, 8, 807-17.
4. M.R. Rekha, C.P. Sharma, Oral delivery of therapeutic protein/peptide for diabetes—future perspectives, International Journal of Pharmaceutics, 2013, 440-48.
5. Maloney CM et al. The rectal administration of MS contin, clinical implications of use in end stage therapy cancer. Am. J. Hosp Care, 1989, 6(4), 34-35, 39.
6. Babul N, Drake Ac, Krishna Murthy TN, Pharmacokinetics of two novel rectal controlled release morphine formulations, Journal for Pain Symptom Management. 1992, 7(7), 400-5.
7. Warren DE, Practical use of rectal medications in palliative care, J. Pain Symptom Management, 1996, 11(6), 378-387.
8. Sarwar G, The protein digestibility-corrected amino acid score method overestimates quality of proteins containing antinutritional factors and of poorly digestible proteins supplemented with limiting amino acids in rats, Journal of Nutrition, 1997, 127, 758-64.
9. Schaafsma G, The protein digestibility-corrected amino acid score, Journal of Nutrition, 2000, 130, 1865S-1867S.
10. Sellmeyer, D.E., Stone, K.L., Sebastian, A. and Cummings, S.R. A high ratio of dietary animal to vegetable protein increases the rate of bone loss and risk of fracture in postmenopausal women, American Journal of Clinical Nutrition 2001, 73, 118-122.
11. St. Jeor, S.T., Howard, B.V., Prewitt, E., Bovee, V., Bazzarre, T. and Eckel, R.H. A statement for healthcare professionals from the nutrition committee of the council on nutrition, physical activity, and metabolism of the American Heart Association. Circulation, 2001, 104, 1869-74.
12. Tarnopolsky MA, Atkinson SA, MacDougall JD, Chesley A, Phillips, SM and Schwarcz H, Evaluation of protein requirements for trained strength athletes, Journal of Applied Physiology, 1992, 73, 1986-95.
13. Tarnolpolsky MA, MacDougall JD, and Atkinson SA, Influence of protein intake and training status on nitrogen balance and lean body mass, Journal of Applied Physiology 1988, 64, 187-93.
14. Tikkanen MJ, Wahala K, Ojala S, Vihma V, and Adlecrerutz H, Effect of soybean phytoestrogen intake on low-density lipoprotein oxidation resistance, Proclamations of the National Academy of Science 1998, 3106-10.
15. Okhamafe AO, Amsden B, Chu W and Goosen MFA, Madulation of protein release from chitosan-alginate microcapsules using the pH-sensitive polymer hydroxypropyl methylcellulose acetate succinate, Journal for Microencapsulation, 1996, 13, 497–508.
16. CO Tacket, MB Sztein, SS Wasserman, G Loson-sky and KL Kotloff, ―Phase 2 Clinical Trial of Attenu-ated Salmonella Enterica Serovar Typhi Oral Live Vector Vaccine CVD 908-htrA in US Volunteers,‖ Infection and Immunity, 2000, 68(3), 1196-1201,2000.
17. GP Li, ZG Liu, B.Liao and NS Zhong, ―Induction of Th1-Type Immune Response by Chitosan Nanoparti-cles Containing Plasmid DNA Encoding House Dust Mite Allergen Der p 2 for Oral Vaccination in Mice,‖ Cellular & Molecular Immunology, 2009, 6(1), 45-50.
18. IS Kim, SK Lee, YM Park, YB Lee and SC Shin, Physicochemical Characterization of Poly(L-lactic acid) and Poly(D,L-lactide-co-glycolide) Nanoparticles with Polyethylenimine as Gene Delivery Carrier,‖ International Journal of Pharmaceutics, 2005, 298(1), 255-62.
19. ANGELINI, ―EPAXAL®—Vaccine for Active Immuni- sation against Hepatitis A,‖ 2011, http,//www,angelini,it/public/schedepharma/epaxal,htm
20. MR Kumar, U Bakowsky and CM Lehr, ―Preparation and Characterization of Cationic PLGA Nanospheres as DNA Carriers, Biomaterials, 2004, 25(10), 1771-77.
21. Y Yue, F Jin, R, Deng J, Cai and Dai, ―Revisit Com-plexation between DNA and Polyethylenimine Effect of Length of Free Polycationic Chains on Gene Transfection, Journal of Controlled Release, 2011, 152(1), 143-151.
22. JL Italia, A Sharp, KC Carter, P Warn and MNVR Kumar, Peroral Amphotericin B Polymer Nanoparti-cles Lead to Comparable or Superior in Vivo Antifungal Activity to That of Intravenous Ambisome® or Fungizone™, 2011, 6(10), 8.
23. R Rupp, SL Rosenthal and LR Stanberry, VivaGel (SPL7013 Gel), A Candidate Dendrimer—Microbicide for the Prevention of HIV and HSV Infection, International Journal of Nanomedicine, 2007, 2(4), 561-6.
24. Gary Gellerman, YosiGilad, Review Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells, Biomedicines, 2019, 4,2-24,
25. Moore JV, Dose-response curve after in vivo experimental chemotherapy, Influence of route of administration on biologicals outcomes, Cancer Chemotherapy in Pharmacology, 1985, 15-91.
26. Benet LZ, Effect of route of administration and distribution on drug action, Journal of Pharmacokinetics Biopharmaceutics, 1978, 6,559–85.
27. Jain A, Gulbake A, Peptide and protein delivery using new drug delivery systems, Critical Reviews in Therapeutic Drug Carrier Systems, PubMed 2013, 30, 293-329.
2. PK Sharma, Sumedha Bansal, Arunabha Banik, Noninvasive Routes of Proteins and Peptides Drug Delivery, Indian Journal of Pharmaceutical Sciences, 2011, 73(4), 367-75.
3. A.A. Kaspar, J.M. Reichert, Future directions for peptide therapeutics development, Drug Discovery Today, 2013, 8, 807-17.
4. M.R. Rekha, C.P. Sharma, Oral delivery of therapeutic protein/peptide for diabetes—future perspectives, International Journal of Pharmaceutics, 2013, 440-48.
5. Maloney CM et al. The rectal administration of MS contin, clinical implications of use in end stage therapy cancer. Am. J. Hosp Care, 1989, 6(4), 34-35, 39.
6. Babul N, Drake Ac, Krishna Murthy TN, Pharmacokinetics of two novel rectal controlled release morphine formulations, Journal for Pain Symptom Management. 1992, 7(7), 400-5.
7. Warren DE, Practical use of rectal medications in palliative care, J. Pain Symptom Management, 1996, 11(6), 378-387.
8. Sarwar G, The protein digestibility-corrected amino acid score method overestimates quality of proteins containing antinutritional factors and of poorly digestible proteins supplemented with limiting amino acids in rats, Journal of Nutrition, 1997, 127, 758-64.
9. Schaafsma G, The protein digestibility-corrected amino acid score, Journal of Nutrition, 2000, 130, 1865S-1867S.
10. Sellmeyer, D.E., Stone, K.L., Sebastian, A. and Cummings, S.R. A high ratio of dietary animal to vegetable protein increases the rate of bone loss and risk of fracture in postmenopausal women, American Journal of Clinical Nutrition 2001, 73, 118-122.
11. St. Jeor, S.T., Howard, B.V., Prewitt, E., Bovee, V., Bazzarre, T. and Eckel, R.H. A statement for healthcare professionals from the nutrition committee of the council on nutrition, physical activity, and metabolism of the American Heart Association. Circulation, 2001, 104, 1869-74.
12. Tarnopolsky MA, Atkinson SA, MacDougall JD, Chesley A, Phillips, SM and Schwarcz H, Evaluation of protein requirements for trained strength athletes, Journal of Applied Physiology, 1992, 73, 1986-95.
13. Tarnolpolsky MA, MacDougall JD, and Atkinson SA, Influence of protein intake and training status on nitrogen balance and lean body mass, Journal of Applied Physiology 1988, 64, 187-93.
14. Tikkanen MJ, Wahala K, Ojala S, Vihma V, and Adlecrerutz H, Effect of soybean phytoestrogen intake on low-density lipoprotein oxidation resistance, Proclamations of the National Academy of Science 1998, 3106-10.
15. Okhamafe AO, Amsden B, Chu W and Goosen MFA, Madulation of protein release from chitosan-alginate microcapsules using the pH-sensitive polymer hydroxypropyl methylcellulose acetate succinate, Journal for Microencapsulation, 1996, 13, 497–508.
16. CO Tacket, MB Sztein, SS Wasserman, G Loson-sky and KL Kotloff, ―Phase 2 Clinical Trial of Attenu-ated Salmonella Enterica Serovar Typhi Oral Live Vector Vaccine CVD 908-htrA in US Volunteers,‖ Infection and Immunity, 2000, 68(3), 1196-1201,2000.
17. GP Li, ZG Liu, B.Liao and NS Zhong, ―Induction of Th1-Type Immune Response by Chitosan Nanoparti-cles Containing Plasmid DNA Encoding House Dust Mite Allergen Der p 2 for Oral Vaccination in Mice,‖ Cellular & Molecular Immunology, 2009, 6(1), 45-50.
18. IS Kim, SK Lee, YM Park, YB Lee and SC Shin, Physicochemical Characterization of Poly(L-lactic acid) and Poly(D,L-lactide-co-glycolide) Nanoparticles with Polyethylenimine as Gene Delivery Carrier,‖ International Journal of Pharmaceutics, 2005, 298(1), 255-62.
19. ANGELINI, ―EPAXAL®—Vaccine for Active Immuni- sation against Hepatitis A,‖ 2011, http,//www,angelini,it/public/schedepharma/epaxal,htm
20. MR Kumar, U Bakowsky and CM Lehr, ―Preparation and Characterization of Cationic PLGA Nanospheres as DNA Carriers, Biomaterials, 2004, 25(10), 1771-77.
21. Y Yue, F Jin, R, Deng J, Cai and Dai, ―Revisit Com-plexation between DNA and Polyethylenimine Effect of Length of Free Polycationic Chains on Gene Transfection, Journal of Controlled Release, 2011, 152(1), 143-151.
22. JL Italia, A Sharp, KC Carter, P Warn and MNVR Kumar, Peroral Amphotericin B Polymer Nanoparti-cles Lead to Comparable or Superior in Vivo Antifungal Activity to That of Intravenous Ambisome® or Fungizone™, 2011, 6(10), 8.
23. R Rupp, SL Rosenthal and LR Stanberry, VivaGel (SPL7013 Gel), A Candidate Dendrimer—Microbicide for the Prevention of HIV and HSV Infection, International Journal of Nanomedicine, 2007, 2(4), 561-6.
24. Gary Gellerman, YosiGilad, Review Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells, Biomedicines, 2019, 4,2-24,
25. Moore JV, Dose-response curve after in vivo experimental chemotherapy, Influence of route of administration on biologicals outcomes, Cancer Chemotherapy in Pharmacology, 1985, 15-91.
26. Benet LZ, Effect of route of administration and distribution on drug action, Journal of Pharmacokinetics Biopharmaceutics, 1978, 6,559–85.
27. Jain A, Gulbake A, Peptide and protein delivery using new drug delivery systems, Critical Reviews in Therapeutic Drug Carrier Systems, PubMed 2013, 30, 293-329.
Crossmark
Statistics
1260 Views | 601 Downloads
How to Cite
1.
Santosh Kumar R, Hemanth R. Proteins and Peptide Drugs: Different Routes of Administration for Their Delivery. JDDT [Internet]. 30Aug.2019 [cited 1May2024];9(4-A):815-9. Available from: https://www.jddtonline.info/index.php/jddt/article/view/3620
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.